

LAHEY CLINIC MEDICAL CENTER

41 MALL ROAD

ROBERT E. WISE, M.D.

CHIEF EXECUTIVE OFFICER
CHAIRMAN, BOARD OF GOVERNORS

BURLINGTON, MASSACHUSETTS 01805

AREA CODE 617 273-5100
CABLE ADDRESS "LAHEYCLIN"

January 2, 1986

John E. Glenn, Ph.D.
Chief, Nuclear Medicine Safety Section B
Division of Radiation Safety and Safeguards
United States Regulatory Commission Region I
631 Park Avenue
King of Prussia, PA 19406

Re: Docket #: 030-01879
License #: 20-05766-02

SUBJECT: Inspection Report #030-01879/85/01

Dear Dr. Glenn:

This letter responds to your letter dated November 22, 1985 to me and supplements Dr. Robert Wenstrup's letter to you dated December 20, 1985.

As a result of the inspection conducted on October 29, 1985, and your letter of November 22, 1985, we have taken the following steps to rectify the violations noted in your letter:

1. When Iodine-131 is used in our department baseline thyroid uptake measurements will be made before handling and at an appropriate time after handling I-131. Records of the thyroid measurements will be maintained. This policy was adopted for therapy doses on October 30, 1985, and extended to all I-131 measurement uses on January 2, 1986.
2. On October 29, 1985 the nuclear medicine technologists were instructed that gauze pads used for injections must not be disposed of as ordinary trash. Since that date our policy has been that all gauze pads must be disposed of as radioactive waste. In addition, as of January 2, 1986 the chief nuclear medicine technologist or her designate will make surveys of the imaging rooms, the injection room, and the radiopharmacy at the beginning and end of every work day. Special attention will be directed to waste baskets and other sites where radioactive contamination may be present. These surveys will be performed in accordance with paragraph 1.2 of the Nuclear Regulatory Guide 8.23, Revision 1, January 1, 1981.

8602040144 860130
REG1 LIC30 PDR
20-05766-02

LAHEY CLINIC FOUNDATION, INC.

MARY AND ARTHUR R. CLAPHAM HOSPITAL
OPERATED BY
LAHEY CLINIC HOSPITAL, INC.

CHARLES A. DANA AMBULATORY CARE CENTER
OPERATED BY
LCF FOUNDATION, INC.

3. As of October 29, 1985 all patients treated with Cs-137 or Ir-192 implants will be surveyed to confirm that all implants have been removed before release from the hospital.

We believe these actions will bring us into compliance with the regulations cited in Appendix A of your letter of November 22, 1985.

Sincerely,



Robert E. Wise, M. D.

REW:smc

cc: Francis J. Scholz, M. D.
Robert S. Wenstrup, Ph.D.
Peter S. Winter, M. D.
Theodore C. M. Lo, M. D.